Using S-nitrosoglutathione to treat lung disease in premature infants
S-Nitrosoglutathione therapy for oxidant disease of the neonatal airways and lung
This study is looking at how a substance called GSNO might help improve lung problems in premature babies with bronchopulmonary dysplasia by reducing inflammation and making it easier for them to breathe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11074687 on NIH RePORTER |
What this research studies
This research investigates the use of S-nitrosoglutathione (GSNO) as a potential therapy for bronchopulmonary dysplasia (BPD), a serious lung condition affecting premature infants. The study aims to understand how GSNO can reverse airway hyperresponsiveness caused by oxidative stress in the lungs. By utilizing a mouse model that mimics the condition, researchers will explore the mechanisms by which GSNO acts as a bronchodilator and anti-inflammatory agent. The findings could lead to new treatment options for infants suffering from this debilitating disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are premature infants diagnosed with bronchopulmonary dysplasia.
Not a fit: Patients who are not premature or do not have bronchopulmonary dysplasia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that improves lung function and reduces the risk of chronic respiratory issues in premature infants.
How similar studies have performed: Previous research has shown promising results with similar therapeutic approaches using GSNO in animal models, indicating potential for success in clinical applications.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Raffay, Thomas Michael — Case Western Reserve University
- Study coordinator: Raffay, Thomas Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.